Department of Neurology, University Hospital Münster, Albert-Schweitzer-Straße 33, 48149 Münster, Germany.
Crit Care. 2011;15(2):129. doi: 10.1186/cc10057. Epub 2011 Mar 9.
Endothelial progenitor cell (EPC) mobilization from the bone marrow was considered to improve outcome after ischemic stroke. Erythropoietin (EPO) might be a potential candidate stroke drug that increases the number of circulating EPCs. In the previous issue of Critical Care, Yip and colleagues investigated the effect of EPO in stroke patients on both clinical outcome and EPC stimulation. Although beneficial effects of EPO were observed, several issues regarding EPO's suitability as a stroke drug remain.
内皮祖细胞（EPC）从骨髓动员被认为可以改善缺血性脑卒中的预后。促红细胞生成素（EPO）可能是一种增加循环 EPC 数量的潜在候选脑卒中药物。在《危重病医学》的前一期中，Yip 及其同事研究了 EPO 对脑卒中患者的临床结局和 EPC 刺激的影响。尽管观察到了 EPO 的有益作用，但 EPO 作为脑卒中药物的适用性仍存在一些问题。
